Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

DARK SECRETS: Benzinga s top ratings upgrades downgrades for november 10 2022 | Vintage Vibes

Upgrades

According to Stifel, the prior rating for Clearside Biomedical Inc (NASDAQ:CLSD) was changed from Hold to Buy. In the third quarter, Clearside Biomedical showed an EPS of $0.13, compared to $0.08 from the year-ago quarter. The current stock performance of Clearside Biomedical shows a 52-week-high of $2.95 and a 52-week-low of $1.00. Moreover, at the end of the last trading period, the closing price was at $1.28.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.